GLP-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in type 2 diabetes patients: a randomised trial.

CONCLUSIONS: Infusion of exenatide did not directly influence MRI-measured exocrine pancreatic excretion in patients with type 2 diabetes. Although long-term studies are warranted, these findings suggest that potential adverse pancreatic effects of GLP-1 receptor agonists are not mediated by changes in exocrine pancreatic secretion. (ClinicalTrials.gov:NCT01744236). PMID: 26640129 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26640129?dopt=Abstract

Source: Diabetes Metab - December 6, 2015 Category: Endocrinology Authors: Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Diamant M, Pieters-van den Bos IC, van Raalte DH, Cahen DL Tags: Diabetes Obes Metab Source Type: research